A large new population study of men over 45 indicates insulin resistance may be an important risk factor for the development of the world’s most common heart valve disease — aortic stenosis (AS).

Published today in the peer-reviewed journal Annals of Medicine, the findings are believed to be the first to highlight this previously unrecognised risk factor for the disease.

It is hoped that by demonstrating this link between AS and insulin resistance — when cells fail to respond effectively to insulin and the body makes more than necessary to maintain normal glucose levels — new avenues for the prevention of the disease could open.

Aortic stenosis is a debilitating heart condition. It causes a narrowing of the aortic valve, restricting blood flow out of the heart. Over time, the valve thickens and stiffens, making the heart work harder to pump blood effectively around the body. If not addressed, this can gradually cause damage that can lead to life-threatening complications, such as heart failure.

People living with AS can take years to develop symptoms, which include chest pain, tiredness, shortness of breath and heart palpitations. Some may never experience symptoms, but may still be at risk of heart failure and death. Previously identified risk factors for AS include age, male sex, high blood pressure, smoking and diabetes.

Insulin resistance, which often develops years before the onset of type 2 diabetes, occurs when cells fail to respond effectively to insulin, the hormone responsible for regulating blood glucose levels. In response, the body makes more insulin to maintain normal glucose levels — leading to elevated blood insulin levels (hyperinsulinemia).

In the current study, researchers analysed data from 10,144 Finnish men aged 45 to 73 years old, all initially free of AS, participating in the Metabolic Syndrome in Men (METSIM) Study. At the start of the study, the researchers measured several biomarkers, including those related to hyperinsulinemia and/or insulin resistance. After an average follow-up period of 10.8 years, 116 men (1.1%) were diagnosed with AS.

The team identified several biomarkers related to insulin resistance — such as fasting insulin, insulin at 30 minutes and 120 minutes, proinsulin, and serum C-peptide — that were associated with increased AS risk. These biomarkers remained significant predictors of AS, even after adjusting for other known risk factors, such as body mass index (BMI) and high blood pressure, or excluding participants with diabetes or an aortic valve malformation.

The researchers then used advanced statistical techniques to isolate key biomarker profiles, identifying two distinct patterns that indicate insulin resistance as a predictor of AS, independent of other cardiovascular risk factors, such as age, blood pressure, diabetes, and obesity.

“This novel finding highlights that insulin resistance may be a significant and modifiable risk factor for AS,” says lead author Dr Johanna Kuusisto, from the Kuopio University Hospital, in Finland.

“As insulin resistance is common in Western populations, managing metabolic health could be a new approach to reduce the risk of AS and improve cardiovascular health in aging populations. Future studies are now warranted to determine whether improving insulin sensitivity through measures such as weight control and exercise can help prevent the condition.”

The major strengths of this study include its large population-based cohort and long follow-up period. However, its limitations include the sole focus on male subjects and the relatively small number of AS cases, which may limit the generalisability of the findings to other populations.



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Before you post, please prove you are sentient.

What is 6 times 5?

Explore More

Popular diabetes and obesity drugs also protect kidneys, study shows

The biggest and most comprehensive analysis of glucagon-like peptide-1 (GLP-1) receptor agonists on kidney and cardiovascular outcomes shows they have significant benefits in people with and without diabetes. Findings were

Study sees potential benefits of obesity drug tirzepatide in tackling type 2 diabetes

Comparison of metabolic targets of GLP-1 RA and GIP RA. The adipocytes located in the gluteofemoral region reflect subcutaneous adipose tissue globally. Credit: eClinicalMedicine (2024). DOI: 10.1016/j.eclinm.2024.102777 Researchers at the

Insulin and metformin combo aids diabetic foot ulcer healing, new study finds

Credit: ACS Pharmacology & Translational Science (2024). DOI: 10.1021/acsptsci.4c00418 People with chronic diabetic foot ulcers could soon have a new way to treat their wounds for faster healing and fewer